Faculty share insights into the overall strategy for managing relapsed/refractory CLL following first-line therapy with venetoclax-based regimens and BTK inhibitors, discussing strategy variations based on prior first-line treatments.
Pirtobrutinib Transforms SOC in Later-Line CLL/SLL
Brown Highlights the Rationale for the RAMP-301 Trial in Low-Grade Serous Ovarian Cancer
Naumann Dives into Case-by-Case Decision-Making in Ovarian and Endometrial Cancer
Revisit the OncLive On Air Episodes From February 2024
Naumann Spotlights Expanding Arsenals and Evolving Decision-Making in Platinum-Resistant Ovarian Cancer
Second-Line Venetoclax Associated With Real-World Cost Savings vs BTK Inhibitors in CLL/SLL
Atezolizumab Plus Chemo Misses Mark in Early-Relapsing Unresectable TNBC
Olaparib/Durvalumab/Fulvestrant Combo Meets PFS End Point in HRR-Altered or MSI ER+/HER2– Breast Cancer
Frontline Atezolizumab Plus Sacituzumab Govitecan Elicits Responses in PD-L1+ Advanced TNBC
Time to Bladder Cancer Treatment Is Similar Among Black and White Patients, But Other Disparities Persist